Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “IMMUNE DESIGN CORP.”

17 pharma patents match "IMMUNE DESIGN CORP." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 17
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 17 pharmaceutical patents matching "IMMUNE DESIGN CORP." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

17 results for “IMMUNE DESIGN CORP.” · 30,257 patents in full index Clear search

  1. US 11365230

    Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof

    IMMUNE DESIGN CORP. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  2. US 11135283

    Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids

    IMMUNE DESIGN CORP. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted
  3. US 10993999

    Materials and methods for producing improved lentiviral vector particles

    IMMUNE DESIGN CORP. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  4. US 10993956

    GLA monotherapy for use in cancer treatment

    IMMUNE DESIGN CORP. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  5. US 10584356

    Multigenome retroviral vector preparations and methods and systems for producing and using same

    IMMUNE DESIGN CORP. · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted
  6. US 10391157

    Materials and methods for producing improved lentiviral vector particles

    IMMUNE DESIGN CORP. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  7. US 10391164

    Vaccines for HSV-2

    IMMUNE DESIGN CORP. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  8. US 10342815

    GLA monotherapy for use in cancer treatment

    IMMUNE DESIGN CORP. · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted
  9. US 10179919

    Multigenome retroviral vector preparations and methods and systems for producing and using same

    IMMUNE DESIGN CORP. · Granted Jan 15, 2019 · Expires Jan 10, 2039

    granted
  10. US 9895435

    Vaccines for HSV-2

    IMMUNE DESIGN CORP. · Granted Feb 20, 2018 · Expires Feb 15, 2038

    granted
  11. US 9713635

    Materials and methods for producing improved lentiviral vector particles

    IMMUNE DESIGN CORP. · Granted Jul 25, 2017 · Expires Jul 20, 2037

    granted
  12. US 9555099

    Vaccines for HSV-2

    IMMUNE DESIGN CORP. · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted
  13. US 9044420

    Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses

    IMMUNE DESIGN CORP. · Granted Jun 2, 2015 · Expires May 28, 2035

    granted
  14. US 8962593

    GLA monotherapy for use in cancer treatment

    IMMUNE DESIGN CORP. · Granted Feb 24, 2015 · Expires Feb 19, 2035

    granted
  15. US 8957047

    GLA monotherapy for use in cancer treatment

    IMMUNE DESIGN CORP. · Granted Feb 17, 2015 · Expires Feb 12, 2035

    granted
  16. US 8323662

    Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein

    IMMUNE DESIGN CORP. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted
  17. US 8187872

    Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

    IMMUNE DESIGN CORP. · Granted May 29, 2012 · Expires May 24, 2032

    granted